Short Interest in Aptorum Group Limited (NASDAQ:APM) Grows By 3,995.8%

Aptorum Group Limited (NASDAQ:APM) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 101,658 shares, a growth of 3,995.8% from the May 31st total of 2,482 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily volume of 583,559 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aptorum Group currently has a consensus rating of “Sell”.

Aptorum Group Stock Down 4.5%

Shares of NASDAQ:APM traded down $0.04 on Thursday, hitting $0.78. The company had a trading volume of 50,933 shares, compared to its average volume of 370,185. Aptorum Group has a 52-week low of $0.65 and a 52-week high of $4.47. The business has a 50 day moving average of $0.89 and a 200 day moving average of $0.94.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.